Clinical Trial

Influence of Donor and Recipient Genetic Polymorphisms on Graft Steatosis After Liver Transplant

Recruiting
View on ClinicalTrials.gov →
Summary
MASH (Metabolic Dysfunction-associated Steatohepatitis) is among the most common indications for liver transplantation.The metabolic syndrome persists after liver transplant and is often further exacerbated among MAFLD patients, thereby leading to recurrence of MAFLD in the allograft. MAFLD is a complex phenotype, dynamic interactions between both genetic and environmental factors are likely to shape disease susceptibility and progression. Genetic and epidemiological studies, indicates strong heritability of hepatic fat content.Family studies demonstrate that first degree relatives of patients with MAFLD are at a much higher risk of the disease than the general population.Most of the data available is regarding Deceased Donor Liver Transplant and Western population.Most studies have studied single gene variant but fatty liver is a polygenic trait.No study was done exclusively in MASH recipients. In this study we aim to study the effect of recipient and donor PNPLA3, MBOAT7 gene variations, and other clinical \& laboratory data on graft liver steatosis in liver transplant recipients. We also propose to compare the outcomes of genetically related donors vs unrelated donors, to know the influence of genetic factors vis-a-vis environmental factors.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-22
Trial Details
NCT Number NCT07685353
Lead Sponsor Institute of Liver and Biliary Sciences, India
Conditions Chronic Liver Disease and Cirrhosis
Enrollment 50 participants
Start Date 2026-07-07
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-21